GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Bionik Laboratories Corp (OTCPK:BNKL) » Definitions » Owner Earnings per Share (TTM)

Bionik Laboratories (Bionik Laboratories) Owner Earnings per Share (TTM) : 0.00 (As of Mar. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Bionik Laboratories Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Bionik Laboratories's Owner Earnings per Share (TTM) ended in Mar. 2023 was $0.00. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Bionik Laboratories's Owner Earnings per Share (TTM) or its related term are showing as below:



BNKL's Price-to-Owner-Earnings is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 20.35
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Bionik Laboratories's Earnings per Share (Diluted) for the three months ended in Mar. 2023 was $-0.20. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.72. It's PE Ratio ratio for today is At Loss.

Bionik Laboratories's EPS without NRI for the three months ended in Mar. 2023 was $-0.20. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.72. It's PE Ratio without NRI ratio for today is At Loss.


Bionik Laboratories Owner Earnings per Share (TTM) Historical Data

The historical data trend for Bionik Laboratories's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionik Laboratories Owner Earnings per Share (TTM) Chart

Bionik Laboratories Annual Data
Trend Dec14 Dec15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.44 -5.03 -2.55 -1.73 -0.57

Bionik Laboratories Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.73 -1.61 -1.61 -0.67 -0.57

Competitive Comparison of Bionik Laboratories's Owner Earnings per Share (TTM)

For the Medical Care Facilities subindustry, Bionik Laboratories's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bionik Laboratories's Price-to-Owner-Earnings Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Bionik Laboratories's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Bionik Laboratories's Price-to-Owner-Earnings falls into.



Bionik Laboratories Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Bionik Laboratories's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -4.95
Depreciation, Depletion and Amortization 0.06
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 0.09
Change In Working Capital 1.01
Shares Outstanding (Diluted Average) 6.98

1. Start with "Net Income" from income statement. Bionik Laboratories's Net Income for the trailing twelve months (TTM) ended in Mar. 2023 was $-4.95 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Bionik Laboratories's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2023 was $0.06 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Bionik Laboratories's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2023 was $0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $0.09 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Bionik Laboratories's 5-Year Average Maintenance Capital Expenditure = $0.09 Mil

5. "Change In Working Capital" is from cashflow statement. Bionik Laboratories's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2023 was $1.01 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Bionik Laboratories's Shares Outstanding (Diluted Average) for the months ended in Mar. 2023 was 6.976 Mil.

Bionik Laboratories's Onwer Earnings Per Share for Mar. 2023 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -4.945 +0.063+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-0.091766516334068+1.013)/6.976
=0.00

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=0.10/0.00
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Bionik Laboratories Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Bionik Laboratories's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Bionik Laboratories (Bionik Laboratories) Business Description

Traded in Other Exchanges
N/A
Address
80 Coolidge Hill Road, Watertown, MA, USA, 02472
Bionik Laboratories Corp is a healthcare company focused on improving the quality of life of millions of people with neurological or mobility impairments by combining artificial intelligence and innovative robotics technology to help individuals from hospital to home regain mobility, enhance autonomy, and regain self-esteem. The company uses artificial intelligence and machine learning technologies to make rehabilitation methods and processes smarter and more intuitive to deliver a greater recovery for patients with neurological or mobility impairments. Its products The InMotion ARM, and InMotion ARM/HAND are robotic therapies for the upper limbs.
Executives
Remi Gaston-dreyfus director, 10 percent owner 46 RUE PIERRE CHARRON, PARIS I0 75008
Charles Matine director 7 RUE GUSTAVE, FLAUBERT, PARIS I0 75017
Andre-jacques Auberton-herve director, officer: Chairman 18 CHEMIN DE LA VIERGE NOIRE, LA TRONCHE I0 38700
Daniel Gonsalves officer: Executive Vice President & CFO 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Loren W. Wass officer: See Remarks 34 HOG HILL ROAD, PEPPERELL MA 01463
Joseph R Martin director
Audrey Thevenon director 4500 WESTBROOK LANE, KENSINGTON MD 20895
Peter Gerald Malone director
Russo Richard Paul Jr officer: Chief Financial Officer 20 PLUNKETT WAY, TEWKSBURY MA 01876
Renaud Bertrand Maloberti officer: Chief Commercial Officer 10 ACORN WAY, GEORGETOWN MA 01833
Timothy A. Mccarthy officer: Chief Commercialization Office C/O BIONIK, 483 BAY STREET, N105, TORONTO A6 M5G 2C9
Eric Michel Dusseux director 1 RUE DU CAPOT, CALUIRE-ET-CUIRE I0 69300
Jules Marc Fried officer: VP - U.S. Operations C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Hermano Igo Krebs officer: Chief Science Officer C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Marc Mathieu director 716 BROOKS AVENUE, VENICE CA 90291